Global Uterine Cancer Therapeutics & Diagnostics Market Size Study & Forecast, by Type of Cancer, by Product and Regional Analysis, 2023-2030

Description

List of Tables

Global Uterine Cancer Therapeutics & Diagnostics Market is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2023-2030. Uterine cancer therapeutics and diagnostics refer to the various treatments and diagnostic methods used to manage and detect uterine cancer, also known as endometrial cancer. Uterine cancer is a type of cancer that develops in the tissues of the uterus, primarily in the lining of the uterus called the endometrium. Increasing healthcare expenditure and growing awareness regarding uterine cancer treatment is anticipated to drive the growth of the Uterine Cancer Therapeutics & Diagnostics Market across the globe

The increasing prevalence of uterine cancer is anticipated to drive the growth of the Uterine Cancer Therapeutics & Diagnostics Market. According to a report published by Cancer.net in 2023, approximately 417,367 individuals worldwide were diagnosed with uterine cancer in the year 2020. Also, it is estimated that over 90% of uterine cancers are found in the endometrium, which is the lining of the uterus. The growing incidence of endometrium carcinoma, primarily attributed to increasing obesity among women, is a key factor driving the Uterine Cancer Therapeutics & Diagnostics Market. Furthermore, the increasing innovation in drug development activities, as well as rising technological advancements in the healthcare sector are presenting various lucrative prospects for the market growth over the anticipated years. However, the high cost associated with the treatment of Uterine Cancer and the low success rate observed in clinical trials for cancer drugs stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Uterine Cancer Therapeutics & Diagnostics Market study include: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. The increasing incidence of uterine cancer and the rising awareness among the general population are the key factors driving the growth of the market in this region. According to the American Cancer Society, approximately 65,620 new cases of uterine body cancer were estimated in the United States in the year 2020. Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as rapid technological advancements in diagnostics and the rapid adoption of new technologies are stipulating the regional market growth

Major market players included in this report are:

AbbVie Inc.
Ability Pharma SA
AstraZeneca PLC
BioMerieux S.A.
Danaher Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc

Recent Developments in the Market:

In April 2022, Roche received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA MMR RxDx Panel, designed for advanced or recurrent endometrial cancer patients. The panel detects microsatellite instability (MSI) and mismatch repair (MMR) deficiencies, which are molecular mechanisms that help correct errors during DNA replication. This testing enables the identification of patients who are eligible for treatment with JEMPERLI (dostarlimab-gxly), a monotherapy anti-PD1 immunotherapy developed by GlaxoSmithKline (GSK) and approved by the FDA.

Global Uterine Cancer Therapeutics & Diagnostics Market Report Scope:

Historical Data: 2020 - 2021
Base Year for Estimation: 2022
Forecast period: 2023-2030
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Type of Cancer, Product, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Cancer:

Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma

By Product:

Therapeutics
Diagnostics

By Region:

North America

U.S.
Canada

Europe

UK
Germany
France
Spain
Italy
ROE

Asia Pacific

China
India
Japan
Australia
South Korea
RoAPAC

Latin America

Brazil
Mexico

Middle East & Africa

Saudi Arabia
South Africa
Rest of Middle East & Africa

Chapter 1. Executive Summary

1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Uterine Cancer Therapeutics & Diagnostics Market, by Region, 2020-2030 (USD Billion)
- 1.2.2. Uterine Cancer Therapeutics & Diagnostics Market, by Type of Cancer, 2020-2030 (USD Billion)
- 1.2.3. Uterine Cancer Therapeutics & Diagnostics Market, by Product, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption

Chapter 2. Global Uterine Cancer Therapeutics & Diagnostics Market Definition and Scope

2.1. Objective of the Study
2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

Chapter 3. Global Uterine Cancer Therapeutics & Diagnostics Market Dynamics

3.1. Uterine Cancer Therapeutics & Diagnostics Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
  - 3.1.1.1. Increasing healthcare expenditure
  - 3.1.1.2. Growing awareness of uterine cancer
- 3.1.2. Market Challenges
  - 3.1.2.1. High Cost of Uterine Cancer Therapeutics & Diagnostics
  - 3.1.2.2. Low success rate observed in clinical trials for cancer drugs
- 3.1.3. Market Opportunities
  - 3.1.3.1. Advancements in Formulation of drug development
  - 3.1.3.2. Increasing technological advancements

Chapter 4. Global Uterine Cancer Therapeutics & Diagnostics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Impact Analysis
4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Uterine Cancer Therapeutics & Diagnostics Market, by Type of Cancer

5.1. Market Snapshot
5.2. Global Uterine Cancer Therapeutics & Diagnostics Market by Type of Cancer, Performance - Potential Analysis
5.3. Global Uterine Cancer Therapeutics & Diagnostics Market Estimates & Forecasts by Type of Cancer 2020-2030 (USD Billion)
5.4. Uterine Cancer Therapeutics & Diagnostics Market, Sub Segment Analysis
- 5.4.1. Endometrial Adenocarcinoma
- 5.4.2. Adenosquamous Carcinoma
- 5.4.3. Papillary Serous Carcinoma
- 5.4.4. Uterine Sarcoma

Chapter 6. Global Uterine Cancer Therapeutics & Diagnostics Market, by Product

6.1. Market Snapshot
6.2. Global Uterine Cancer Therapeutics & Diagnostics Market by Product, Performance - Potential Analysis
6.3. Global Uterine Cancer Therapeutics & Diagnostics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
6.4. Uterine Cancer Therapeutics & Diagnostics Market, Sub Segment Analysis
- 6.4.1. Therapeutics
- 6.4.2. Diagnostics

Chapter 7. Global Uterine Cancer Therapeutics & Diagnostics Market, Regional Analysis

7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Uterine Cancer Therapeutics & Diagnostics Market, Regional Market Snapshot
7.4. North America Uterine Cancer Therapeutics & Diagnostics Market
- 7.4.1. U.S. Uterine Cancer Therapeutics & Diagnostics Market
  - 7.4.1.1. Type of Cancer breakdown estimates & forecasts, 2020-2030
  - 7.4.1.2. Product breakdown estimates & forecasts, 2020-2030
- 7.4.2. Canada Uterine Cancer Therapeutics & Diagnostics Market
7.5. Europe Uterine Cancer Therapeutics & Diagnostics Market Snapshot
- 7.5.1. U.K. Uterine Cancer Therapeutics & Diagnostics Market
- 7.5.2. Germany Uterine Cancer Therapeutics & Diagnostics Market
- 7.5.3. France Uterine Cancer Therapeutics & Diagnostics Market
- 7.5.4. Spain Uterine Cancer Therapeutics & Diagnostics Market
- 7.5.5. Italy Uterine Cancer Therapeutics & Diagnostics Market
- 7.5.6. Rest of Europe Uterine Cancer Therapeutics & Diagnostics Market
7.6. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market Snapshot
- 7.6.1. China Uterine Cancer Therapeutics & Diagnostics Market
- 7.6.2. India Uterine Cancer Therapeutics & Diagnostics Market
- 7.6.3. Japan Uterine Cancer Therapeutics & Diagnostics Market
- 7.6.4. Australia Uterine Cancer Therapeutics & Diagnostics Market
- 7.6.5. South Korea Uterine Cancer Therapeutics & Diagnostics Market
- 7.6.6. Rest of Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market
7.7. Latin America Uterine Cancer Therapeutics & Diagnostics Market Snapshot
- 7.7.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market
- 7.7.2. Mexico Uterine Cancer Therapeutics & Diagnostics Market
7.8. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market
- 7.8.1. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market
- 7.8.2. South Africa Uterine Cancer Therapeutics & Diagnostics Market
- 7.8.3. Rest of Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Chapter 8. Competitive Intelligence

8.1. Key Company SWOT Analysis
- 8.1.1. Company 1
- 8.1.2. Company 2
- 8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. AbbVie Inc.
  - 8.3.1.1. Key Information
  - 8.3.1.2. Overview
  - 8.3.1.3. Financial (Subject to Data Availability)
  - 8.3.1.4. Product Summary
  - 8.3.1.5. Recent Developments
- 8.3.2. Ability Pharma SA
- 8.3.3. AstraZeneca PLC
- 8.3.4. BioMerieux S.A.
- 8.3.5. Danaher Corporation
- 8.3.6. Eli Lilly and Company
- 8.3.7. F. Hoffmann-La Roche Ltd
- 8.3.8. GlaxoSmithKline PLC
- 8.3.9. Johnson & Johnson Services, Inc.
- 8.3.10. Merck & Co., Inc

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

LIST OF TABLES

TABLE 1. Global Uterine Cancer Therapeutics & Diagnostics Market, report scope
TABLE 2. Global Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by Type of Cancer 2020-2030 (USD Billion)
TABLE 4. Global Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by Product 2020-2030 (USD Billion)
TABLE 5. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. U.S. Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. Canada Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 19. Canada Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. UK Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 22. UK Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. Germany Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 25. Germany Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. France Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 28. France Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. Italy Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 31. Italy Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Spain Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 34. Spain Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. RoE Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 37. RoE Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. China Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 40. China Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. India Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 43. India Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. Japan Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 46. Japan Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. South Korea Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 49. South Korea Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. Australia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 52. Australia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. RoAPAC Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 55. RoAPAC Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. Brazil Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 58. Brazil Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Mexico Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 61. Mexico Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. RoLA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 64. RoLA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 67. South Africa Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. RoMEA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Uterine Cancer Therapeutics & Diagnostics Market
TABLE 70. List of primary sources, used in the study of global Uterine Cancer Therapeutics & Diagnostics Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

FIG 1. Global Uterine Cancer Therapeutics & Diagnostics Market, research methodology
FIG 2. Global Uterine Cancer Therapeutics & Diagnostics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Uterine Cancer Therapeutics & Diagnostics Market, key trends 2022
FIG 5. Global Uterine Cancer Therapeutics & Diagnostics Market, growth prospects 2023-2030
FIG 6. Global Uterine Cancer Therapeutics & Diagnostics Market, porters 5 force model
FIG 7. Global Uterine Cancer Therapeutics & Diagnostics Market, pest analysis
FIG 8. Global Uterine Cancer Therapeutics & Diagnostics Market, value chain analysis
FIG 9. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Uterine Cancer Therapeutics & Diagnostics Market, regional snapshot 2020 & 2030
FIG 15. North America Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
FIG 16. Europe Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)